Single-Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults
|
|
- Brenda Cobb
- 5 years ago
- Views:
Transcription
1 Single-Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults Anne M. McDonnell, Pharm.D., Kristi L. Lenz, Pharm.D., Debra A. Frei-Lahr, M.D., John Hayslip, M.D., and Philip D. Hall, Pharm.D. Rasburicase is currently approved at a dosage of mg/kg once/day for 5 days in pediatric patients with cancer to lower plasma uric acid concentrations and manage tumor lysis syndrome (TLS). Information on rasburicase dosing in adults is limited, with some data on using rasburicase as a single dose instead of multiple daily doses. Therefore, we evaluated the efficacy of a single dose of rasburicase for preventing or managing TLS in adults. We collected retrospective data for 11 adults with hematologic malignancies who received a single 6-mg dose of rasburicase. All patients received intravenous hydration with urinary alkalinization and allopurinol; however, due to adverse reactions, two patients received short courses of allopurinol. Only patients at high risk for TLS (e.g., large tumor burden, increasing uric acid concentration) or those with TLS received rasburicase. The single dose of rasburicase 6 mg resulted in a median mg/kg dose (range mg/kg). The single 6-mg dose rapidly lowered uric acid concentrations in 10 of the 11 patients. The median uric acid concentration of 11.7 mg/dl (range mg/dl) declined to 2.0 mg/dl (range mg/dl) within a day after rasburicase administration (p=0.022). In these 10 patients, uric acid concentrations remained low despite subsequent chemotherapy, and none required additional rasburicase doses. The only patient who did not respond to the single 6-mg rasburicase dose was a morbidly obese man (259 kg, body mass index 87 kg/m 2 ) who subsequently responded to an additional dose of rasburicase 12 mg. These results warrant further investigation of a single 6-mg dose of rasburicase in adults with TLS or at high-risk for developing TLS. Key Words: rasburicase, lymphoma, leukemia, tumor lysis syndrome, uric acid. (Pharmacotherapy 2006;26(6): ) From the Department of Pharmacy Services, Medical University Hospital (Dr. McDonnell), the Department of Pharmacy and Clinical Sciences, South Carolina College of Pharmacy (Drs. Lenz and Hall), the Department of Medicine, College of Medicine (Drs. Frei-Lahr and Hayslip), and Hollings Cancer Center (Drs. Frei-Lahr and Hall), Medical University of South Carolina, Charleston, South Carolina. Address reprint requests to Philip D. Hall, Pharm.D., Department of Pharmacy and Clinical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina Campus, 280 Calhoun Street, Box , Charleston, SC Tumor lysis syndrome (TLS) occurs as a result of rapid malignant cell lysis and is manifested by electrolyte abnormalities such as hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia. It may occur spontaneously or be precipitated by chemotherapy, corticosteroids, radiation, hormonal agents, or biologic response modifiers. Tumor lysis syndrome is most profound in the presence of rapidly proliferating tumors, chemosensitive disease, or malignancies with a high tumor burden. The hyperuricemia of
2 SINGLE-DOSE RASBURICASE IN ADULTS McDonnell et al TLS results when purine nucleic acids are released by tumor cell lysis and metabolized into uric acid. At high concentrations, uric acid can precipitate and form an obstructive nephropathy, contributing to acute renal failure. Some patients may require dialysis secondary to hyperuricemia and its subsequent electrolyte abnormalities. 1, 2 Prevention of TLS requires aggressive hydration with urinary alkalinization and allopurinol, with the goal of minimizing electrolyte abnormalities and uric acid induced nephropathy. Allopurinol has been available in the United States since 1966 and is effective in the prophylactic management of hyperuricemia by inhibiting xanthine oxidase. Allopurinol has no effect on existing uric acid. Rasburicase is a recombinant urate oxidase approved by the United States Food and Drug Administration (FDA) in It is indicated for prevention of hyperuricemia in children with malignancies that have a high occurrence of TLS. Rasburicase catalyzes the breakdown of uric acid into allantoin and hydrogen peroxide. Allantoin is up to 10 times more soluble than uric acid and has a decreased rate of precipitation in the renal tubules. 3 Currently, rasburicase is FDA approved at a dosage of mg/kg once/day for 5 days in pediatric patients to lower plasma uric acid concentration and manage TLS. 4 Limited data are available regarding rasburicase use in adults. The largest trial was the Groupe d Etude des Lymphomes de l Adulte Trial on Rasburicase Activity in Adult Lymphoma study (GRAAL1). 5 In this trial, 100 adult patients with non-hodgkin s lymphoma received rasburicase 0.2 mg/kg/day for 3 7 days, starting either the day before or the first day of chemotherapy. Of these patients, 95 who received three or more doses responded to rasburicase, resulting in decreased uric acid concentrations. All patients maintained low uric acid concentrations throughout treatment. In several small case series, a single dose of rasburicase was administered as an alternative to multiple daily doses in children. In one report, three children with newly diagnosed leukemia were treated with a single, fixed dose of rasburicase 4.5 mg (range mg/kg) before the start of chemotherapy to prevent TLS. 6 None of the three experienced hyperuricemia after the single dose, and none required dialysis. In another case series, four adults received rasburicase for management of hyperuricemia secondary to TLS. 7 Doses ranged from mg (range mg/kg) for one to three doses. Uric acid concentrations were successfully lowered in all four patients. In a third series, a single dose of rasburicase 0.15 mg/kg was administered to two children and six adults with hematologic malignancies. 8 In all patients, rasburicase caused a rapid and sustained lowering of serum uric acid concentrations, and no patient required dialysis. Because of the limited information and the promising results in adults given a single dose of rasburicase, we evaluated the use of a single-dose strategy in adult patients. Also, because of the high cost of rasburicase, the single, fixed dose may be cost-effective. We describe our experience with the administration of a single dose of rasburicase 6 mg in 11 adults with advanced hematologic malignancies. We chose the 6-mg fixed dose for our first patient (72.7 kg) based on the lowest effective milligram/kilogram dose (0.08 mg/kg) used in one of the case series discussed above. 6 Methods We selected the patients for this series by searching the pharmacy database and identifying cases known to us. All uric acid concentrations were stored in ice when they were sent to the laboratory. Cost information came from the 2005 Drug Topics Red Book. 9 A Wilcoxon signed rank test was used to compare uric acid concentrations before and after administration of the rasburicase dose. Case Reports 807 Patient No. 1 A 64-year-old woman diagnosed with B-cell non-hodgkin s lymphoma from a mandibular lesion came to the hospital 12 days after surgery with increasing abdominal pain, weakness, and fatigue. Pertinent laboratory test results indicated that her white blood cell count was 10.4 x 10 3 /mm 3 (normal range x 10 3 /mm 3 ), platelet count 600 x 10 3 /mm 3 ( x 10 3 /mm 3 ), serum creatinine concentration 1.8 mg/dl ( mg/dl), calcium level 14.5 mg/dl ( mg/dl), and blood urea nitrogen (BUN) level 45 mg/dl (8 20 mg/dl). She was admitted to the hospital and immediately given intravenous hydration, intravenous pamidronate 60 mg, and allopurinol. On hospital day 2, her white blood cell count was 7.9 x 10 3 /mm 3, uric acid 11.7 mg/dl ( mg/dl), serum creatinine 1.7 mg/dl, calcium 12
3 808 PHARMACOTHERAPY Volume 26, Number 6, 2006 Table 1. Laboratory and Dosing Data for the 11 Patients Who Received a Single Dose of Rasburicase 6 mg Time from Dose Uric Acid Level Administration Rasburicase Before After to Decreased Serum Creatinine Actual Dose Relative to Patient Rasburicase Rasburicase Uric Acid Level Level Before Dose Weight Actual Weight No. (mg/dl) (mg/dl) (hrs) (mg/dl) (kg) (mg/kg) a b Median c a Patient no. 6 was readmitted for relapse of his acute lymphoblastic leukemia and received another 6-mg dose of rasburicase. b Patient no. 11 received a second, double dose (12 mg) of rasburicase the next day because his uric acid level decreased only slightly after the first (6-mg) dose. c p= mg/dl, and lactate dehydrogenase (LDH) 908 IU/L ( IU/L). Because of the patient s high tumor burden and worsening renal function compared with her preoperative baseline serum creatinine level (1.1 mg/dl), she was given a single dose of rasburicase 6 mg. The next morning, her uric acid level had declined to 4 mg/dl and remained below the upper limit of normal for the rest of her hospital stay (Table 1). Within 5 days of administration of the rasburicase dose, the patient s serum creatinine level returned to baseline and BUN to 20 mg/dl. She subsequently received treatment for management of her lymphoma. Patient No. 2 A 45-year-old woman with a history of renal cell carcinoma with subsequent nephrectomy, depression, and hypertension was diagnosed with relapsed non-hodgkin s lymphoma after coming to the clinic for her second cycle of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Clinic work-up revealed progressive lymphadenopathy, lymphocytosis, and LDH level of 1640 IU/L. At that time the patient was given additional rituximab and was admitted to the hospital for administration of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-cvad). Due to her significant tumor burden, she also received aggressive hydration with urinary alkalinization and a single dose of rasburicase 6 mg for TLS prophylaxis. Before she received the rasburicase dose, the patient s uric acid level was 8.2 mg/dl; this decreased to 3.9 mg/dl after approximately 3 hours. Her uric acid concentration continued to decline over the next 16 hours (Table 1). Uric acid and serum creatinine levels remained below the upper limit of normal during her chemotherapy treatment course. Patient No. 3 A 49-year-old woman with newly diagnosed B- cell non-hodgkin s lymphoma developed spontaneous tumor lysis with subsequent acute renal failure before the start of her chemotherapy. The patient s white blood cell count was 19.3 x 10 3 /mm 3, uric acid level 11.7 mg/dl, LDH level 580 IU/L, and serum creatinine concentration 3 mg/dl. She was given aggressive hydration with urinary alkalinization, allopurinol, and a single dose of rasburicase 6 mg. Allopurinol was discontinued after she developed a rash. After the rasburicase dose was administered, the patient s uric acid level decreased from 11.7 mg/dl to 2.1 mg/dl and remained below the upper limit of normal for the next 7 days (Table 1). On day 7 after administration of the rasburicase dose, CHOP was administered. However, the patient subsequently developed renal failure and
4 SINGLE-DOSE RASBURICASE IN ADULTS McDonnell et al required dialysis 3 times/week. She was given additional doses of rasburicase for prophylaxis during her hospital stay and required dialysis for approximately 15 days of her hospital stay. At discharge, however, she no longer required dialysis. Patient No. 4 A 56-year-old man went to a local hospital with complaints of increasing weakness, and inability to ambulate or eat. On arrival at our facility, his laboratory test results indicated a white blood cell count of 204 x 10 3 /mm 3, uric acid level 11.8 mg/dl, LDH level 503 IU/L, and serum creatinine concentration 2.4 mg/dl. He received hydration with urinary alkalinization, allopurinol, hydroxyurea, leukapheresis, and a single dose of rasburicase 6 mg. His uric acid level decreased to 2.9 mg/dl (Table 1). Work-up results led to a diagnosis of acute myeloid leukemia M4, and the patient received induction with cytarabine plus daunorubicin. Without additional rasburicase, his serum creatinine concentration decreased to 1.3 mg/dl within 5 days and returned to baseline within 10 days. Patient No. 5 A 62-year-old man with a history significant for hypertension, diabetes mellitus, gout, and chronic renal failure was transferred to our facility for management of a newly discovered posterior fossa cerebellar lesion. His baseline serum creatinine level was 2 mg/dl. The patient subsequently was diagnosed with chronic myelomonocytic leukemia. On admission, his laboratory test results revealed a white blood cell count of 185 x 10 3 /mm 3 with 5% blast cells, uric acid level 14.9 mg/dl, calcium level 8.3 mg/dl, LDH level 1884 IU/L, serum creatinine level 2.5 mg/dl, and BUN level 49 mg/dl. The patient received hydration with urinary alkalinization, leukapheresis, dexamethasone, and hydroxyurea. Within 24 hours of admission, he was given a single dose of rasburicase 6 mg; 5.5 hours after administration of the dose, his uric acid level decreased from 14.7 to 7.4 mg/dl and continued to decline to 5.1 mg/dl (Table 1). His uric acid level remained in the normal range for the rest of his hospital stay. Serum creatinine concentration remained elevated, peaking at 3.1 mg/dl, but declined to 2.1 mg/dl by discharge, consistent with the patient s baseline chronic renal failure. His BUN level continued to rise during his 10-day hospital stay and was 72 mg/dl 809 at discharge. The patient was discharged to home with instructions to follow up as an outpatient for future management of his head lesion and leukemia. Patient No. 6 A 22-year-old man with a history of Philadelphia chromosome-positive, acute lymphoblastic leukemia came to the hospital with increasing nausea, decreased appetite, and left upper quadrant pain over the previous week. Laboratory test results revealed a white blood cell count of 63.8 x 10 3 /mm 3 with 66% blast cells, platelet count 34 x 10 3 /mm 3, serum creatinine concentration 1.1 mg/dl, LDH level 887 IU/L, and uric acid level 7.5 mg/dl. He was admitted to the hospital. Because of his high risk for tumor lysis, he was given aggressive hydration with urinary alkalinization, allopurinol, and a single dose of rasburicase 6 mg before the start of chemotherapy with hyper-cvad and imatinib. The patient s uric acid level decreased to 0.5 mg/dl after the rasburicase dose (Table 1). He tolerated chemotherapy well, and his creatinine and uric acid levels remained stable for the rest of his hospital stay. This patient was readmitted for a second relapse of his acute lymphoblastic leukemia 2 months later and was treated with high-dose cytarabine and mitoxantrone. Significant laboratory findings on admission were a white blood cell count of 195 x 10 3 /mm 3 with 15% blast cells, platelet count 34 x 10 3 /mm 3, serum creatinine concentration 1.4 mg/dl, LDH level 1234 IU/L, uric acid level 11.8 mg/dl, and an undetectable phosphorus level. He received hydration with urinary alkalinization, allopurinol, and a single dose of rasburicase 6 mg. His uric acid concentration was 5.7 mg/dl 3 hours after administration of the rasburicase dose and continued to decline. It increased slightly but did not exceed the upper limit of normal during the patient s chemotherapy course. His serum creatinine concentration also continued to decline and remained within the normal range during the rest of his hospital stay. Patient No. 7 A 69-year-old man with a history of myelodysplastic syndrome, coronary artery disease, chronic renal insufficiency, and abdominal aortic aneurysm came to the clinic with a 20-lb weight loss over the preceding 2 3 months and increasing dyspnea while climbing stairs.
5 810 Laboratory test results revealed a white blood cell count of 229 x 10 3 /mm 3 with 50% blast cells. He was admitted to the hospital; laboratory test results indicated a white blood cell count of 265 x 10 3 /mm 3, serum creatinine concentration 2.7 mg/dl, LDH level 1233 IU/L, and uric acid level 16.8 mg/dl. The patient received leukapheresis, hydration with urinary alkalinization, allopurinol, hydroxyurea, and a single dose of rasburicase 6 mg. His uric acid concentration was 7.1 mg/dl 4 hours later and continued to decline (Table 1). Due to the patient s declining mental status and organ failure, the family declined further medical treatment, and he was discharged to a long-term care facility. Patient No. 8 A 63-year-old woman came to our facility with increased bruising and petechiae, rectal bleeding, and a white blood cell count of 46 x 10 3 /mm 3 noted on routine physical examination. Her history was significant for osteoporosis, hemorrhoids, and uterine cancer treated with radiation therapy and hysterectomy. She was admitted for further management and was diagnosed with acute myeloid leukemia. Significant laboratory findings on admission were a white blood cell count of 54.1 x 10 3 /mm 3 with 95% blast cells, platelet count 9 x 10 3 /mm 3, serum creatinine concentration 1.0 mg/dl, LDH level 1359 IU/L, and uric acid level 4.1 mg/dl. Tumor lysis prophylaxis was started with allopurinol and hydration with urinary alkalinization. Allopurinol was discontinued after the patient developed a fever thought to be a reaction to the allopurinol. Induction chemotherapy was started with cytarabine and daunorubicin. The patient received a single dose of rasburicase 6 mg on day 3 of chemotherapy, after her uric acid level increased to 7.4 mg/dl. Uric acid concentration promptly decreased to 0.8 mg/dl and remained in the low normal range for the rest of her chemotherapy course (Table 1). Patient No. 9 A 35-year-old man with a history of chronic myeloid leukemia in blast crisis was admitted to our facility for possible leukapheresis. He had first gone to a local hospital with increasing pain; laboratory test results revealed a white blood cell count of 96 x 10 3 /mm 3. Pertinent laboratory test results on admission to our facility indicated a white blood cell count of 100 x 10 3 /mm 3 with 7% blast cells, serum creatinine concentration 1.5 PHARMACOTHERAPY Volume 26, Number 6, 2006 mg/dl, LDH level 2069 IU/L, and uric acid level 10.1 mg/dl. Treatment was begun with hydroxyurea, hydration with alkalization, and allopurinol. The next day, the patient received a single dose of rasburicase 6 mg and induction chemotherapy with cytarabine and daunorubicin. His uric acid level, which was 7.3 mg/dl before the rasburicase dose, decreased to 1.1 mg/dl the next day and remained below the upper limit of normal throughout the rest of his hospital stay (Table 1). Patient No. 10 A 60-year-old man came to our facility with a history of liver transplantation due to hepatitis C. He was diagnosed as positive for human immunodeficiency virus and had renal failure; he subsequently was diagnosed with Burkitt s lymphoma. The patient initially received hydration with urinary alkalinization, allopurinol, and a single dose of rasburicase 6 mg. On the day of rasburicase administration, pertinent laboratory findings indicated a white blood cell count of 4.03 x 10 3 /mm 3, serum creatinine concentration 6.4 mg/dl, LDH level 401 IU/L, and uric acid level 10.3 mg/dl. His uric acid level decreased to 3.4 mg/dl 3.5 hours after the rasburicase dose was administered and continued to decline (Table 1). The patient subsequently received rituximab, corticosteroids, and intrathecal methotrexate. Before the start of therapy with hyper-cvad, the patient developed a renal vein thrombosis, hypotension, and respiratory distress; he died despite resuscitative measures. Patient No. 11 A 41-year-old, morbidly obese man (weight 259 kg, height 68 in., body mass index 87 kg/m 2 ) with a history of hypertension, diabetes mellitus, and heart failure was transferred to our facility after first going to another facility with weakness, anemia, hematuria, and rectal bleeding. On admission, laboratory test results indicated a white blood cell count of 104 x 10 3 /mm 3 with 90% blast cells, platelet count 43 x 10 3 /mm 3, serum creatinine concentration 3.2 mg/dl, uric acid level 17.4 mg/dl, and LDH level 1109 IU/L. The patient was treated with hydration, allopurinol, and a single dose of rasburicase 6 mg. The next day, the patient s uric acid level remained at 15.4 mg/dl, and the decision was made to administer a second, double dose (12 mg) of rasburicase. The day after administration
6 SINGLE-DOSE RASBURICASE IN ADULTS McDonnell et al of this dose, the patient s uric acid level decreased to 1.4 mg/dl (Table 1). Subsequently, he received prophylactic rasburicase 12 mg with his induction chemotherapy. Discussion In 10 of the 11 cases presented, the combination of allopurinol, intravenous hydration with urinary alkalinization, and a single dose of rasburicase 6 mg was effective in lowering uric acid concentration. In addition, renal function returned to baseline status in seven of the eight patients with renal dysfunction secondary to tumor lysis. Patient no. 10, whose renal function did not recover, died secondary to sepsis in the intensive care unit. In a retrospective case series, adult patients who had cancer with hyperuricemia received a single dose of rasburicase mg along with allopurinol and hydration. 10 The largest group, 12 patients, received a single dose of rasburicase 3 mg that resulted in a median decrease of 46% (range 31 68%) in uric acid concentration. No patient experienced clinically significant renal dysfunction. Only two patients in that case series received a single dose of rasburicase 6 mg. In our case series, which involved a single 6-mg dose, we observed a median decrease of 83% (range %) in uric acid concentration. This median decrease from 11.7 to 2.0 mg/dl was statistically significant (p=0.022; Table 1). Although a direct comparison of these two small case series is biased, the results suggest a doseresponse relationship with rasburicase. Patient no. 11 was a morbidly obese patient who did not respond to the initial single 6-mg dose of rasburicase. Data are limited regarding rasburicase dosing for morbidly obese adults. One case report described administration of a single dose of rasburicase 11 mg (0.2 mg/kg based on ideal body weight) in a 136-kg patient with chronic myeloid leukemia in blast crisis, likely experiencing tumor lysis. 11 Before the rasburicase dose was given, the patient s uric acid level was 11.9 mg/dl; this decreased to 5.1 mg/dl at 4 hours and 1.9 mg/dl at 48 hours after the dose. Another case report describing a morbidly obese patient also used rasburicase 0.2 mg/kg based on ideal body weight a single dose of rasburicase 12 mg. 10 The patient s serum uric acid concentration decreased from 11 mg/dl at baseline to 0.4 mg/dl 12 hours after the dose was given, and remained low. In contrast, when our morbidly obese patient (patient no. 11) was given the fixed dose of rasburicase 6 mg ( mg/kg based on actual body weight, 0.09 mg/kg based on ideal body weight), the response was not optimal; his uric acid level decreased from 17.4 to 15.4 mg/dl 7 hours after the dose was given (Table 1). However, after the second, 12- mg dose ( mg/kg based on actual, 0.18 mg/kg based on ideal body weight), his uric acid rapidly declined from 15.4 to 1.4 mg/dl. This limited information indicates that a single dose of rasburicase, dosed at mg/kg based on ideal body weight, may be effective for morbidly obese patients. Rasburicase is available only in single-use 1.5- mg vials; therefore, rounding doses to 1.5-mg increments is prudent. Another limitation is its cost; the average wholesale price for a package of three 1.5-mg vials of rasburicase is $ , or $386.78/1.5-mg vial. 9 Extrapolating the approved pediatric dose of 0.15 mg/kg to the dose for a 75- kg adult results in one dose of rasburicase mg/day for 5 days. This amounts to an average wholesale price of $ /day, and $14, for 5 days. A single dose of rasburicase 6 mg would cost $ , for an overall savings of $12,957.13/patient. Conclusion Tumor cell lysis can be a potentially lifethreatening complication that requires quick and aggressive management to prevent acute renal failure. Findings from these case reports warrant further investigation of using a single 6-mg dose of rasburicase, along with allopurinol, intravenous hydration, and urinary alkalinization in adults with TLS or adults who have a high risk of developing TLS. A fixed dose of rasburicase 6 mg for nonobese patients and mg/kg for morbidly obese patients (based on ideal body weight and rounded to the contents of a vial) may be a reasonable, efficient, and cost-effective option in the management of adults with hyperuricemia secondary to tumor lysis or those at risk of TLS. References Bishop MR, Cairo MS, Coccia PF. Tumor lysis syndrome. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Clinical oncology. Orlando, FL: Churchill Livingstone, 2004: Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004;116:
7 812 PHARMACOTHERAPY Volume 26, Number 6, Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19: Sanofi-Synthelabo. Elitek (rasburicase) package insert. New York, NY; Coiffler B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-hodgkin s lymphoma: results of the GRAAL1 (groupe d etude des lymphomes de l adulte trial on rasburicase activity in adult lymphoma) study. J Clin Oncol 2003;21: Lee AC, Li CH, So KT, Chan R. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003;37: Hummel M, Buchheidt D, Reiter S, Bergmann J, Hofheinz R, Hehlmann R. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003;17: Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase in patients receiving chemotherapy. Leuk Res 2005:29: Fleming T, ed. Drug topics red book. Montvale, NJ: Thomson PDR, 2005: Trifilio S, Tallman M, Singhal S, Gordon L, Evens A, Mehta J. Low-dose recombinant urate oxidase (rasburicase) is effective in hyperuricemia [abstr]. Blood 2004;104(suppl 1):905a. 11. Arnold TM, Reuter JP, Delman BS, Shanholtz CB. Use of single-dose rasburicase in an obese female. Ann Pharmacother 2004;38:
Tumor Lysis Syndrome Nephrology Grand Rounds Tuesday, July 27 th, 2010 Aditya Mattoo
Tumor Lysis Syndrome Nephrology Grand Rounds Tuesday, July 27 th, 2010 Aditya Mattoo Outline Background/Definition Epidemiology/Risk Stratification Pathophysiology Treatment Renal Replacement Therapy Background/Definition
More informationAnalysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase
MOLECULAR AND CLINICAL ONCOLOGY 6: 955-959, 2017 Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase EISEKI USAMI 1, MICHIO KIMURA 1,
More informationOncology Emergency Essentials: Addressing Tumor Lysis Syndrome in Your Practice
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationGUIDELINE FOR THE MANAGEMENT AND PREVENTION OF ACUTE TUMOUR LYSIS SYNDROME IN HAEMATOLOGICAL MALIGNANCIES
GUIDELINE FOR THE MANAGEMENT AND PREVENTION OF ACUTE TUMOUR LYSIS SYNDROME IN HAEMATOLOGICAL MALIGNANCIES Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target
More informationManaging patients with bulky cancers
SIOP PODC Supportive Care Education (ICON 2016) Presentation Date: 23 rd January 2016 Recording Link at www.cure4kids.org: https://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p2pjfjp8nha
More informationFrequency of Tumor Lysis Syndrome in Aggressive and Slow Introduction Chemotherapy in Children with ALL
Original Article Frequency of Tumor Lysis Syndrome in Aggressive and Slow Introduction Chemotherapy in Children with ALL Downloaded from ijpho.ssu.ac.ir at 1:59 IRDT on Friday July 1th 2018 Hashemi A 1,
More informationOutcome of Tumor Lysis Syndrome with Hydration and Alkalinization in Children with Acute Lymphoblastic Leukemia
Bangladesh Journal of Medical Science Vol. 11 No. 04 Oct 12 Original article Outcome of Tumor Lysis Syndrome with Hydration and Alkalinization in Children with Acute Lymphoblastic Leukemia Sultana A 1,
More informationAnnouncements. Learning Objectives. Introduction. Prevention and Treatment of an Oncologic Emergency: Focus on Tumor Lysis Syndrome
Prevention and Treatment of an Oncologic Emergency: Focus on Tumor Lysis Syndrome Kamakshi V. Rao, Pharm.D., BCOP Oncology Clinical Pharmacy Specialist University of North Carolina Hospitals and Clinics
More information2.1 mmol/l or 25% increase from baseline mmol/l or 25% decrease from baseline
22.1 Hyperleukocytosis and tumour lysis syndrome The guideline is addressed for ALL patients with hyperleukocytosis (WBC 100 x109/l) only and should not be used without modifications in case of other diseases
More informationSubject: Rasburicase (Elitek )
09-J2000-43 Original Effective Date: 10/15/15 Reviewed: 08/01/18 Revised: 09/15/18 Subject: Rasburicase (Elitek ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF
More informationGuidelines for the Prevention of Tumour Lysis Syndrome
1.0 Introduction For the purposes of this guideline, tumour lysis syndrome (TLS) is defined as metabolic derangement resulting from abrupt and massive breakdown of malignant cells and the release of intracellular
More informationAvoiding Dialysis in Tumour Lysis Syndrome: Is Urate Oxidase Effective? A Case Report and Review of Literature
Case Report 679 Avoiding Dialysis in Tumour Lysis Syndrome: Is Urate Oxidase Effective? A Case Report and Review of Literature Wan-Yee Teo, 1 MBBS, MRCPCH (Lond), Tsee-Foong Loh, 2 MBBS, MMed (Paeds),
More informationTumor lysis syndrome (TLS) is a group of PROCEEDINGS CURRENT AND EMERGING TREATMENT OPTIONS FOR PATIENTS WITH TUMOR LYSIS SYNDROME * Sima Jeha, MD
CURRENT AND EMERGING TREATMENT OPTIONS FOR PATIENTS WITH TUMOR LYSIS SYNDROME * Sima Jeha, MD ABSTRACT Tumor lysis syndrome (TLS) is a life-threatening complication of cancer chemotherapy in which hyperuricemia
More informationSpontaneous Tumor Lysis Syndrome in Small Cell Lung Cancer
Open Access Case Report DOI: 10.7759/cureus.1017 Spontaneous Tumor Lysis Syndrome in Small Cell Lung Cancer Venkatkiran Kanchustambham 1, Swetha Saladi 2, Setu Patolia 2, David Stoeckel 2 1. Pulmonary
More informationIranian Journal of Blood & Cancer. The Efficacy of Single Dose Rasburicase in Prevention or Treatment of Tumor Lysis Syndrome in Children
IJBC 2016; 8(2): 33-37 Iranian Journal of Blood & Cancer Journal Home Page: www.ijbc.ir Original Article The Efficacy of Single Dose Rasburicase in Prevention or Treatment of Tumor Lysis Syndrome in Children
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: September 15, 2016 Gazyva Description Gazyva (obinutuzumab)
More informationRituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description
More informationHaematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital
Haematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital Case Number 1 43 year old male presenting with fevers, abdominal distension and weight gain over 2 weeks.
More informationHypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome
Maie et al. SpringerPlus 2014, 3:501 a SpringerOpen Journal RESEARCH Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome Open Access Koichiro Maie 1, Yasuhisa Yokoyama
More informationGOOD MORNING! July 3, 2014
GOOD MORNING! July 3, 2014 OUR PATIENT 4yo Female with: 2 days of fever, sore throat, swollen nodes in neck and abdominal pain PMH: Tonsillectomy age 2 Immunizations: UTD NKDA DIFFERENTIAL: OUR PATIENT
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CODOX-M.DOC CONTROLLED DOC NO: HCCPG B115 CSIS Regimen Name: R-CODOXM. Rituximab + CODOX-M
Rituximab + CODOX-M Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Burkitt
More informationHematologic Emergencies. Udomsak Bunworasate Chulalongkorn University
Hematologic Emergencies Udomsak Bunworasate Chulalongkorn University Hematologic Emergencies Hyperleukocytosis Tumor lysis syndrome SVC syndrome Spinal cord compression Hypercalcemia 1. Hyperleukocytosis
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationHospital, Chengdu , China. Hospital, Chengdu , China
Hyperuricemia and acute renal failure secondary to spontaneous tumor lysis syndrome in low risk myelodysplastic syndrome. Yunlin Feng, M.D. 1,, Tao Jiang 2 Correspondence: Yunlin Feng fengyunlin@tsinghua.org.cn
More informationEasy Trick to Spot Leukemia for Pediatricians
Easy Trick to Spot Leukemia for Pediatricians Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital Most Common Pediatric Cancers Age 0-14 Leukemia 32%
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: March 16, 2018 Gazyva Description Gazyva (obinutuzumab)
More informationDevelopment of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy
www.bioinformation.net Hypothesis Volume 10(11) Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy Mahmood Rasool 1 *, Arif Malik 2, Muhammad
More informationLeukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College
Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,
More informationGuidelines for use of RASBURICASE in adult Haematology and Oncology patients
Network Guidance Document Guidelines for use of RASBURICASE in adult Haematology and Oncology patients Status: Expiry Date: Version Number: Publication Date: Final September 2013 6 September 2011 Page
More informationLimitations of Use: (1) Duzallo is not recommended for the treatment of asymptomatic hyperuricemia.
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.63 Subject: Duzallo Page: 1 of 5 Last Review Date: December 8, 2017 Duzallo Description Duzallo (lesinurad
More informationDOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More information4/20/2015. Chemotherapy in the Infusion Clinic: Patient Electrolyte Imbalance Considerations. Learning Objectives. Ambulatory Oncology Infusion Center
Chemotherapy in the Infusion Clinic: Patient Electrolyte Imbalance Considerations Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Explore the benefits
More informationELIGIBILITY: Newly diagnosed acute promyelocytic leukemia (APL) with low to intermediate risk (WBC less than 10 x 10 9 /L)
BCCA Protocol Summary for First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid) Protocol Code Tumour Group Contact
More informationBC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab
BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab Protocol Code Tumour Group Contact Physicians LYCLLFLUDR Lymphoma Dr.
More informationADULT Updated: September 4, 2018
Updated: September 4, 2018 Regimen Reference Order ARIA: LYMP [R-CHOP alt. R-DHAP] Planned Course: Indication for Use: Every 21 days for 6 cycles (R-CHOP given on cycles 1, 3 and 5; R-DHAP given on cycles
More informationELIGIBILITY: Newly diagnosed acute promyelocytic leukemia (APL) with high risk (WBC more than 10 x 10 9 /L)
BC Cancer Protocol Summary for First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin (All-Trans Retinoic Acid) and DAUNOrubicin Protocol Code
More informationWhat is the Incidence of Kidney Stones after Chemotherapy in Patients with Lymphoproliferative or Myeloproliferative Disorders?
ORIGINAL ARTICLE Vol. 40 (6): 772-780, November - December, 2014 doi: 10.1590/S1677-5538.IBJU.2014.06.08 What is the Incidence of Kidney Stones after Chemotherapy in Patients with Lymphoproliferative or
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Supportive Care for NHL Tumor Lysis Syndrome (TLS) Laboratory hallmarks of TLS:
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationSponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: sanofi-aventis Drug
More informationNCCP Chemotherapy Regimen. Obinutuzumab and Chlorambucil Therapy
INDICATIONS FOR USE: Obinutuzumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities
More informationBCCA Protocol Summary for Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and rituximab
BCCA Protocol Summary for Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and rituximab Protocol Code Tumour Group Contact Physician LYIVACR Leukemia/BMT
More informationKYMRIAH (tisagenlecleucel)
KYMRIAH (tisagenlecleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationContents Page No. 1. Outline of Procedure 2. Area of Application 3. Objective 4. Stages of the Process 5. Responsibilities
Contents Page No. 1. Outline of Procedure 3 2. Area of Application 3 3. Objective 3 4. Stages of the Process 3 5. Responsibilities 8 6. Other useful information 8 7. References 8 Page 2 of 10 Clinical
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationJC Hofmann, MD 1,2 ; KM Grant, MD 3 ; DD Kiprov, MD 1,2. Apheresis Care Group, 2. Division of Immunotherapy, 3
Greater Than Ninety Percent of Patients with Acute Leukemia and Hyperleukocytosis Who Receive Leukocytapheresis Treatment Successfully Undergo Induction Chemotherapy: Follow-up Analysis of Data from 2006-2013
More informationKrystexxa. Krystexxa (pegloticase) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.14 Subject: Krystexxa Page: 1 of 5 Last Review Date: March 16, 2018 Krystexxa Description Krystexxa
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationNorth West London Cancer Network
GUIDELINES FOR THE MANAGEMENT OF ADULT ACUTE LEUKAEMIA INITIAL MANAGEMENT CONSIDERATIONS N.B.: If AML is suspected definitively diagnosed, please ensure that the patient is transferred immediately f treatment
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma. TREATMENT INTENT Palliative or curative depending on context.
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationHematologic Emergency. Le Wang, MD, PhD Hematology & Oncology
Hematologic Emergency Le Wang, MD, PhD Hematology & Oncology Severe Thrombocytopenia (ITP) Clinical: bleeding risk 0 no bleeding; 1 minimal bleeding after trauma; 2 spontaneous but selflimited bleeding;
More informationInpatient Antineoplastic Medication Administration And Associated Drug Costs: Institution of a Hospital Policy Limiting Inpatient Administration
Inpatient Antineoplastic Medication Administration And Associated Drug Costs: Institution of a Hospital Policy Limiting Inpatient Administration Alexandra E. Foster, PharmD; and David J. Reeves, PharmD,
More informationtumor lysis syndrome
2.0 ANCC CONTACT HOURS Oncology Emergency series Recognizing and preventing tumor lysis syndrome By Roberta Kaplow, PhD, APRN-CCNS, AOCNS, CCRN, and Karen Iyere, MSN, RN TUMOR LYSIS SYNDROME (TLS) is one
More informationM Y ELO I D D I FFER ENTIATI O N OPENS UP THE POSSIBILITIES
IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationTreatment results in ALL
Treatment results in ALL Adults Complete remission (CR) 80-85% Leukemia-free survival (LFS) 30-40% Children Complete remission (CR) 95-99% Leukemia-free survival (LFS) 70-80% Combination chemotherapy in
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More information9/3/2014. Conflict of Interest Disclosures. Learning Objectives. Definitions of Nausea/Vomiting. Definitions of Nausea/Vomiting
Conflict of Interest Disclosures LeAnn B. Norris Teva Pharmaceuticals Last Chance Webinar 2014 Oncology Supportive Care LeAnn B. Norris, PharmD, BCPS, BCOP Assistant Professor South Carolina College of
More information(212) (347)
EMBARGOED FOR MONDAY, JUNE 21, 2010: 3:00 P.M. EST For immediate release: June 21, 2010 Media Contact: Curtis Allen (212) 733-2096 (347) 443-5252 Investors Contact: Suzanne Harnett (212) 733-8009 Pfizer
More informationAcute tumor lysis syndrome (ATLS), although
ACUTE TUMOR LYSIS SYNDROME Michele Cohen, DVM, DACVIM (Oncology) College of Veterinary Medicine Auburn University Auburn, Alabama Acute tumor lysis syndrome (ATLS), although uncommon, can be a serious
More informationDosing and Administration Guide for ARZERRA
Dosing and Administration Guide for ARZERRA INDICATIONS for ARZERRA (ofatumumab) In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL)
More informationEngineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL
Engineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL Diana Schreier, Pharm.D., M.B.A. Pharmacy Grand Rounds October 17, 2017 2017 MFMER
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, Gemcitabine, Dexamethasone &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma or high grade T cell non-hodgkin
More informationThings to never miss in the office. Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC
Things to never miss in the office Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC Presenter Disclosure Faculty / Speaker s name: Brett Houston / Leonard Minuk Relationships with commercial
More informationCase presentation. serum uric acid = 11.5 mg/dl 24-hour uric acid excretion = 300 mg
GOUT 55 y/o male 12 hours pain in my big toe & ankle went to bed last night feeling fine felt as if had broken toe this morning similar problems in right ankle & left wrist Case presentation lab studies
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationIndex. Note: Page numbers of article numbers are in boldface type.
Index Note: Page numbers of article numbers are in boldface type. A Abdomen, acute, as cancer emergency, 381 399 in cancer patients, etiologies unique to, 390 392 in perforation, 388 surgery of, portal
More informationManufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Brand Name: Mylotarg Generic Name: gentuzumab ozogamicin Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Drug Class: CD33-directed antibody-drug conjugate Uses: Labeled Uses: Newly-diagnosed
More informationUrate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Title. Cheuk, DKL; Chiang, AKS; Chan, GCF; Ha, SY
Title Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer Author(s) Cheuk, DKL; Chiang, AKS; Chan, GCF; Ha, SY Citation Cochrane Database of Systematic Reviews,
More informationGAZYVA Dosing and Administration Guide
GAZYVA Dosing and Administration Guide Indications GAZYVA is a CD20-directed cytolytic antibody and is indicated: In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at
More informationLymphoma Case Scenario 1
Lymphoma Case Scenario 1 HISTORY: A 23-year-old healthy female presented with a month-long history of persistent headache of increasing severity. She noted episodic nausea and vomiting in association with
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationRasburicase 1.5 mg/ml powder and solvent for concentrate for solution for infusion. FASTURTEC
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory This package insert is continually updated. Please read carefully before using a new pack. Rasburicase 1.5 mg/ml powder
More informationSAALT3W Sarcoma Dr. Meg Knowling. Protocol Code Tumour Group Contact Physician
BCCA Protocol Summary for Etoposide, Ifosfamide-Mesna (SAIME) Alternating with vincristine, DOXOrubicin and Cyclophosphamide (with or without Mesna)(SAVAC or SAVACM) with Filgrastim Support at a THREE
More informationNote: There are other bendamustine protocols, ensure this is the correct one for a given patient.
INDICATIONS 1 st line treatment for follicular lymphoma with FLIPI score 2 or higher: (NICE TA513- BLUETEQ required) Rituximab refractory follicular lymphoma (progression on R-chemo, R-maintenance or within
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationFasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.
1. NAME OF THE MEDICINAL PRODUCT Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 ml of Fasturtec concentrate
More informationPRODUCT MONOGRAPH. (rasburicase) Powder for Injection Professed Standard
PRODUCT MONOGRAPH Pr FASTURTEC (rasburicase) Powder for Injection Professed Standard 1.5 mg/vial (1.5 mg/ml/vial) Uricolytic Agent sanofi-aventis Canada Inc. Date of Revision: 2150 St. Elzear Blvd. West
More informationObinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case
Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationAntiemetic protocol for rare emetogenic chemotherapy - see protocol SCNAUSEA
BCCA Protocol Summary for Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with obinutuzumab and Chlorambucil Protocol Code Tumour Group Contact Physician
More informationZURAMPIC (lesinurad) oral tablet
ZURAMPIC (lesinurad) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationJo Abraham MD Division of Nephrology University of Utah
Jo Abraham MD Division of Nephrology University of Utah 68 year old male presented 3 weeks ago with a 3 month history of increasing fatigue He reported a 1 week history of increasing dyspnea with a productive
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationTe-Fu Weng, Kung-His Wu, Ching-Tien Peng Department of Hematology and Oncology Children s Hospital of China Medical University
Successful resuscitation using extracorporeal membrane oxygenation for fetal hyperkalemia and refractory ventricular fibrillation due to severe tumor lysis syndrome Te-Fu Weng, Kung-His Wu, Ching-Tien
More information1-844-FAX-A360 ( )
1-844-ASK-A360 (1-844-275-2360) 1-844-FAX-A360 (1-844-329-2360) www.myaccess360.com For more information, call AstraZeneca Access 360 at 1-844-ASK-A360, Monday through Friday, 8 am to 8 pm ET. IMFINZI
More information